Zymeworks Inc (ZYME)
NASDAQ:ZYME
Want to see ZYME full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.36Last Year’s EPS
0.03Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.Company Guidance
Near-term Regulatory Catalysts for Zanatumab
PDUFA date set for 08/25/2026 in first-line GEA (U.S.) and sBLA filing completed in China, creating visible near-term commercialization pathway with partners Jazz and BeiGene and potential for meaningful milestone and royalty revenue.
Material Potential Milestone Upside
Potential near-term milestone payments include $250M upon U.S. approval from Jazz and $15M upon China approval from BeiGene; management cites anticipated regulatory milestone payments of $440M across U.S., Europe, Japan and China that underpin financial runway assumptions.
Strong Cash Position and Runway
Cash, cash equivalents and marketable securities of $403.8M as of 03/31/2026, up from $270.6M as of 12/31/2025 (+49.2%), with management expecting existing cash plus anticipated milestone payments to fund operations beyond 2028 (assumes milestones).
Active Share Repurchase Program
Company has used ~$95.8M of its $125M repurchase authorization (~76.6% utilized) to acquire ~3.93M shares at an average price of $24.37; historically retired ~8.3M shares (~$155.8M deployed) representing >10% of common shares outstanding, reflecting disciplined capital allocation to increase per-share value.
Compelling Phase 1 Data for ZW191 (FRα ADC)
ZW191 showed notable activity in heavily pretreated ovarian and endometrial cohorts: ovarian cohort ≥30% tumor regression in 68%, any tumor shrinkage in 85%, disease control 94%, ORR 56% across dose levels; at 6.4–9.6 mg/kg confirmed ORR 61% and disease control in all patients at that range. Endometrial: ≥30% tumor regression in 50%, tumor shrinkage in 70%, disease control 80%, ORR 40% (all doses); at 6.4–9.6 mg/kg ORR 57% and disease control 86%. Median follow-up ~7 months with durability signals.
Pan‑RAS ADC Platform and Preclinical Progress
Presented three new preclinical pan‑RAS ADC candidates (ZW439: Claudin 18.2; ZW427: L1CAM; ZW418: biparatopic PTK7) at AACR and proprietary TOPA payload advancement. Lead pan‑RAS ADC showed favorable xenograft efficacy, bystander activity, and promising NHP tolerability with no observed body weight loss, skin or GI toxicity up to 120 mg/kg in tolerability studies. ADCs are DAR‑8 formats enabling tumor-selective payload delivery.
ZW251 Trial Expansion and TriTCE Progress
ZW251 protocol broadened to include additional tumor types (e.g., squamous NSCLC and germ cell tumors) based on GPC3 expression rationale; ZW209 is IND‑ready and TriTCE portfolio remains a prioritized long‑term asset class.
Operational and Leadership Strengthening
Appointed new CFO and General Counsel and completed full-time appointments for commercial and R&D heads to support capital allocation, dealmaking, and strategic execution.
ZYME Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ZYME Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $26.60 | $23.89 | -10.19% |
Mar 02, 2026 | $23.29 | $23.31 | +0.09% |
Nov 06, 2025 | $17.90 | $16.46 | -8.04% |
Aug 07, 2025 | $12.16 | $12.02 | -1.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Zymeworks Inc (ZYME) report earnings?
Zymeworks Inc (ZYME) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Zymeworks Inc (ZYME) earnings time?
Zymeworks Inc (ZYME) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZYME EPS forecast?
ZYME EPS forecast for the fiscal quarter 2026 (Q2) is -0.36.